Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-07612577 in Healthy Adults
NCT05554237Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ceftibuten + avibactam-tomilopil in complicated urinary tract infection (cUTI) (3 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Concentration, Time for Cmax and 3 more. Started Oct 2022; status: completed.
02
Drugs
ceftibuten + avibactam-tomilopil
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT05554237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554237.